This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Akouos Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

-45.4%

Tasa de crecimiento de los beneficios

75.7%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera	-51.2%
Margen neto	n/a
Última actualización de beneficios	30 Sep 2022

Actualizaciones de resultados anteriores recientes

No hay actualizaciones

Recent updates

Here's Why We're Not Too Worried About Akouos' (NASDAQ:AKUS) Cash Burn Situation

Jun 26

Akouos names Kathy Reape as chief development officer

May 07

We Think Akouos (NASDAQ:AKUS) Can Afford To Drive Business Growth

Mar 04

Did Akouos, Inc. (NASDAQ:AKUS) Insiders Buy Up More Shares?

Jan 10

Akouos (NASDAQ:AKUS) Is In A Good Position To Deliver On Growth Plans

Nov 18

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Akouos. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:AKUS Ingresos, gastos y beneficios (USD Millions)
Fecha	Beneficios	Gastos G+A	Gastos de I+D
30 Sep 22	-93	26	67
30 Jun 22	-96	25	71
31 Mar 22	-98	24	74
31 Dec 21	-87	22	65
30 Sep 21	-74	21	53
30 Jun 21	-64	20	45
31 Mar 21	-54	17	38
31 Dec 20	-49	15	34
30 Sep 20	-46	11	35
30 Jun 20	-41	7	31
31 Mar 20	-30	5	25
31 Dec 19	-26	3	20

Ingresos de calidad: AKUS is currently unprofitable.

Margen de beneficios creciente: AKUS is currently unprofitable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: AKUS is unprofitable, and losses have increased over the past 5 years at a rate of 45.4% per year.

Acelerando crecimiento: Unable to compare AKUS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Beneficios vs. Industria: AKUS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (60.8%).

Rentabilidad financiera

Alta ROE: AKUS has a negative Return on Equity (-51.2%), as it is currently unprofitable.

This company listing is no longer active

Akouos Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Recent updates

Akouos, Inc.(NasdaqGS:AKUS) dropped from NASDAQ Composite Index

Akouos, Inc. Announces Executive and Board Changes

Akouos, Inc.(NasdaqGS:AKUS) dropped from NASDAQ Biotechnology Index

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Akouos, Inc. (NasdaqGS:AKUS) from 5AM Venture Management, LLC, New Enterprise Associates, Inc. and others for approximately $460 million.

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Akouos, Inc. (NasdaqGS:AKUS) from 5AM Venture Management, LLC, New Enterprise Associates, Inc. and others.

Is Akouos (NASDAQ:AKUS) In A Good Position To Deliver On Growth Plans?

Akouos, Inc. Receives FDA Clearance of Its IND Application for AK-OTOF, A Gene Therapy Intended for the Treatment of OTOF-Mediated Hearing Loss

Akouos stock rises 11% on FDA nod to start gene therapy trial for hearing loss

Akouos, Inc. Announces Resignation of Chris Smith as Member of the Board of Directors, Effective August 15, 2022

Akouos, Inc.(NasdaqGS:AKUS) dropped from Russell 2500 Index

We Think Akouos (NASDAQ:AKUS) Needs To Drive Business Growth Carefully

Akouos, Inc. Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear At the American Society of Gene and Cell Therapy 25Th Annual Meeting

Price target decreased to US$23.50

We Think Akouos (NASDAQ:AKUS) Can Afford To Drive Business Growth

Companies Like Akouos (NASDAQ:AKUS) Are In A Position To Invest In Growth

Akouos, Inc.(NasdaqGS:AKUS) dropped from Russell 2500 Growth Index

Here's Why We're Not Too Worried About Akouos' (NASDAQ:AKUS) Cash Burn Situation

Akouos, Inc. Presents Nonclinical Data Supporting Future Clinical Development of Ak-Otof and Ak-Antivegf At the American Society of Gene and Cell Therapy 24Th Annual Meeting

Akouos names Kathy Reape as chief development officer

We Think Akouos (NASDAQ:AKUS) Can Afford To Drive Business Growth

New 90-day low: US$17.45

Akouos and Blueprint Genetics Announce the Resonate Program to Improve Access to Genetic Testing for Individuals with Auditory Neuropathy

Did Akouos, Inc. (NASDAQ:AKUS) Insiders Buy Up More Shares?

Akouos (NASDAQ:AKUS) Is In A Good Position To Deliver On Growth Plans

New 90-day low: US$17.99

Akouos, Inc. Appoints Sachiyo Minegishi as Chief Financial Officer

Desglose de ingresos y gastos
Beta

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

This company listing is no longer active

Akouos Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Recent updates

Akouos, Inc.(NasdaqGS:AKUS) dropped from NASDAQ Composite Index

Akouos, Inc. Announces Executive and Board Changes

Akouos, Inc.(NasdaqGS:AKUS) dropped from NASDAQ Biotechnology Index

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Akouos, Inc. (NasdaqGS:AKUS) from 5AM Venture Management, LLC, New Enterprise Associates, Inc. and others for approximately $460 million.

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Akouos, Inc. (NasdaqGS:AKUS) from 5AM Venture Management, LLC, New Enterprise Associates, Inc. and others.

Is Akouos (NASDAQ:AKUS) In A Good Position To Deliver On Growth Plans?

Akouos, Inc. Receives FDA Clearance of Its IND Application for AK-OTOF, A Gene Therapy Intended for the Treatment of OTOF-Mediated Hearing Loss

Akouos stock rises 11% on FDA nod to start gene therapy trial for hearing loss

Akouos, Inc. Announces Resignation of Chris Smith as Member of the Board of Directors, Effective August 15, 2022

Akouos, Inc.(NasdaqGS:AKUS) dropped from Russell 2500 Index

We Think Akouos (NASDAQ:AKUS) Needs To Drive Business Growth Carefully

Akouos, Inc. Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear At the American Society of Gene and Cell Therapy 25Th Annual Meeting

Price target decreased to US$23.50

We Think Akouos (NASDAQ:AKUS) Can Afford To Drive Business Growth

Companies Like Akouos (NASDAQ:AKUS) Are In A Position To Invest In Growth

Akouos, Inc.(NasdaqGS:AKUS) dropped from Russell 2500 Growth Index

Here's Why We're Not Too Worried About Akouos' (NASDAQ:AKUS) Cash Burn Situation

Akouos, Inc. Presents Nonclinical Data Supporting Future Clinical Development of Ak-Otof and Ak-Antivegf At the American Society of Gene and Cell Therapy 24Th Annual Meeting

Akouos names Kathy Reape as chief development officer

We Think Akouos (NASDAQ:AKUS) Can Afford To Drive Business Growth

New 90-day low: US$17.45

Akouos and Blueprint Genetics Announce the Resonate Program to Improve Access to Genetic Testing for Individuals with Auditory Neuropathy

Did Akouos, Inc. (NASDAQ:AKUS) Insiders Buy Up More Shares?

Akouos (NASDAQ:AKUS) Is In A Good Position To Deliver On Growth Plans

New 90-day low: US$17.99

Akouos, Inc. Appoints Sachiyo Minegishi as Chief Financial Officer

Desglose de ingresos y gastosBeta

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Desglose de ingresos y gastos
Beta